Skip to main content

Advertisement

SpringerLink
Log in

Amyloid-plaque imaging in early and differential diagnosis of dementia

  • Invited Review Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The increasing life expectancy in our society results in a continuously growing number of patients suffering from neurodegenerative disorders, particularly Alzheimer’s disease (AD). Apart from the deleterious consequences for patients and their relatives, this issue has also alarming effects on our social systems. These facts have justified increased scientific efforts regarding the identification of basic pathomechanisms of dementia and the development of new treatment options. Increased production of specific proteins and their pathologic aggregation in the brain appears to be a pathomechanism which occurs early in the course of many different neurodegenerative diseases. Among the most well-known of these protein aggregations are amyloid plaques, which arise from the aggregation of the β-amyloid protein. Currently, this amyloid-aggregation pathology is regarded as a key pathology, playing a causal role in the development of AD. Consequently, modern therapy approaches are directed towards this target. Limited access to brain tissue has so far restricted the definite diagnosis of AD to postmortem histopathological assessment of brain tissue. For the same reason, a clear association between extent of amyloid deposition pathology and clinical course of AD has not been established so far. However, particularly with regard to new therapeutic options, a reliable in vivo diagnosis is required. Modern molecular imaging tracers such as [11C]PIB do now open the possibility to visualize amyloid depositions in vivo, using positron emission tomography. This type of “in vivo histopathology” approach allows the characterization of neurodegenerative disorders on the basis of the underlying pathology rather than on their symptomatic appearance. In this manuscript, we will discuss the options of amyloid-plaque imaging regarding early and differential diagnosis of different forms of dementia as well as for patient selection for therapy trials and for objective therapy monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34:561–6.

    Article  PubMed  Google Scholar 

  2. Alafuzoff I. The pathology of dementias: an overview. Acta Neurol Scand Suppl. 1992;139:8–15.

    Article  CAS  PubMed  Google Scholar 

  3. Aguero-Torres H, Winblad B, Fratiglioni L. Epidemiology of vascular dementia: some results despite research limitations. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S15–20.

    Article  PubMed  Google Scholar 

  4. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer’s disease incidence rates. Alzheimers Dement. 2008;4:316–23.

    Article  PubMed  Google Scholar 

  5. Bickel H. Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany. Gesundheitswesen. 2000;62:211–8.

    Article  CAS  PubMed  Google Scholar 

  6. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–22.

    Article  PubMed  Google Scholar 

  7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.

    Article  CAS  PubMed  Google Scholar 

  8. Alzheimer’s Association. 2008 Alzheimer’s disease facts and figures. Alzheimers Dement. 2008;4:110–33.

    Google Scholar 

  9. Alzheimer’s Association. 2009 Alzheimer’s disease facts and figures. Alzheimers Dement. 2009;5(3):27–31.

    Google Scholar 

  10. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125–32.

    Article  CAS  PubMed  Google Scholar 

  11. Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426(6968):900–4.

    Article  CAS  PubMed  Google Scholar 

  12. Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci. 1999;249(Suppl 3):14–22.

    PubMed  Google Scholar 

  13. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.

    Article  CAS  PubMed  Google Scholar 

  14. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106–13.

    Article  CAS  PubMed  Google Scholar 

  15. Hull M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer’s disease: how far have we come? Drugs. 2006;66:2075–93.

    Article  PubMed  Google Scholar 

  16. Forstl H, Kurz A. Clinical features of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 1999;249:288–90.

    Article  CAS  PubMed  Google Scholar 

  17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.

    CAS  PubMed  Google Scholar 

  18. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988;38:1688–93.

    CAS  PubMed  Google Scholar 

  19. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–53.

    CAS  PubMed  Google Scholar 

  20. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.

    Article  CAS  PubMed  Google Scholar 

  21. Arnaiz E, Almkvist O, Ivnik RJ, Tangalos EG, Wahlund LO, Winblad B, et al. Mild cognitive impairment: a cross-national comparison. J Neurol Neurosurg Psychiatry. 2004;75:1275–80.

    Article  CAS  PubMed  Google Scholar 

  22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.

    Article  CAS  PubMed  Google Scholar 

  23. Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology. 2006;67:441–5.

    Article  CAS  PubMed  Google Scholar 

  24. Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer’s disease. J Clin Neurosci. 2005;12:221–30.

    Article  PubMed  Google Scholar 

  25. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007;68:828–36.

    Article  CAS  PubMed  Google Scholar 

  26. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008;70:191–9.

    Article  CAS  PubMed  Google Scholar 

  27. Jack CR Jr, Shiung MM, Weigand SD, O’Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227–31.

    Article  PubMed  Google Scholar 

  28. Ries ML, Carlsson CM, Rowley HA, Sager MA, Gleason CE, Asthana S, et al. Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. J Am Geriatr Soc. 2008;56:920–34.

    Article  PubMed  Google Scholar 

  29. Wahlund LO, Almkvist O, Blennow K, Engedahl K, Johansson A, Waldemar G, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imag. 2005;16:427–37.

    Article  Google Scholar 

  30. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24–35.

    PubMed  Google Scholar 

  31. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.

    Article  CAS  PubMed  Google Scholar 

  32. Henriksen G, Yousefi BH, Drzezga A, Wester HJ. Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imag. 2008;35(Suppl 1):S75–81.

    Article  CAS  Google Scholar 

  33. Lockhart A. Imaging Alzheimer’s disease pathology: one target, many ligands. Drug Discov Today. 2006;11:1093–9.

    Article  CAS  PubMed  Google Scholar 

  34. Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. J Neurochem. 2009;109:623–30.

    Article  CAS  PubMed  Google Scholar 

  35. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009;50:191–7.

    Article  PubMed  Google Scholar 

  36. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007;130:2837–44.

    Article  PubMed  Google Scholar 

  37. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174–84.

    Article  CAS  PubMed  Google Scholar 

  38. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer’s disease. Brain. 2008;131:1845–53.

    Article  CAS  PubMed  Google Scholar 

  39. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med. 2007;48:547–52.

    Article  CAS  PubMed  Google Scholar 

  40. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–7.

    Article  CAS  PubMed  Google Scholar 

  41. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45.

    Article  PubMed  Google Scholar 

  42. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65:1304–9.

    Article  PubMed  Google Scholar 

  43. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65:927–34.

    Article  CAS  PubMed  Google Scholar 

  44. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456–65.

    Article  CAS  PubMed  Google Scholar 

  45. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310–23.

    Article  CAS  PubMed  Google Scholar 

  46. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.

    Article  CAS  PubMed  Google Scholar 

  47. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–56.

    Article  CAS  PubMed  Google Scholar 

  48. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA. 2009;106:6820–5.

    Article  CAS  PubMed  Google Scholar 

  49. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487–94.

    Article  CAS  PubMed  Google Scholar 

  50. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–52.

    Article  CAS  PubMed  Google Scholar 

  51. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia. 2008;46:1688–97.

    Article  CAS  PubMed  Google Scholar 

  52. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509–17.

    Article  PubMed  Google Scholar 

  53. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:2607–15.

    Article  CAS  PubMed  Google Scholar 

  54. Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428–37.

    Article  CAS  PubMed  Google Scholar 

  55. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365–71.

    Article  CAS  PubMed  Google Scholar 

  56. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–63.

    Article  CAS  PubMed  Google Scholar 

  57. Drzezga A. Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies. Eur J Nucl Med Mol Imag. 2008;35(Suppl 1):S4–11.

    Article  Google Scholar 

  58. Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med. 2002;16:515–25.

    Article  PubMed  Google Scholar 

  59. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology. 2007;69:356–9.

    Article  CAS  PubMed  Google Scholar 

  60. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903–10.

    Article  CAS  PubMed  Google Scholar 

  61. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718–25.

    Article  CAS  PubMed  Google Scholar 

  62. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431–4.

    Article  PubMed  Google Scholar 

  63. Herholz K. PET studies in dementia. Ann Nucl Med. 2003;17:79–89.

    Article  PubMed  Google Scholar 

  64. McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.

    Article  PubMed  Google Scholar 

  65. Ikeda M, Ishikawa T, Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2004;17:265–8.

    Article  PubMed  Google Scholar 

  66. Snowden JS. Semantic dysfunction in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 1999;10(Suppl 1):33–6.

    Article  PubMed  Google Scholar 

  67. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.

    CAS  PubMed  Google Scholar 

  68. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3.

    Article  CAS  PubMed  Google Scholar 

  69. Shi J, Shaw CL, Du Plessis D, Richardson AM, Bailey KL, Julien C, et al. Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol (Berl). 2005;110:501–12.

    Article  Google Scholar 

  70. Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH. The pathological basis of semantic dementia. Brain. 2005;128:1984–95.

    Article  PubMed  Google Scholar 

  71. Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol. 2005;62:925–30.

    Article  PubMed  Google Scholar 

  72. Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imag. 2008;35:100–6.

    Article  Google Scholar 

  73. Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205–12.

    Article  CAS  PubMed  Google Scholar 

  74. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease. Neuroimage. 2008;39:619–33.

    Article  PubMed  Google Scholar 

  75. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388–401.

    Article  PubMed  Google Scholar 

  76. Sadowski M, Pankiewicz J, Scholtzova H, Li YS, Quartermain D, Duff K, et al. Links between the pathology of Alzheimer’s disease and vascular dementia. Neurochem Res. 2004;29:1257–66.

    Article  CAS  PubMed  Google Scholar 

  77. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229–34.

    Article  PubMed  Google Scholar 

  78. Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H, et al. Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol. 2008;65:540–4.

    Article  PubMed  Google Scholar 

  79. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain. 2006;129:2856–66.

    Article  PubMed  Google Scholar 

  80. Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, et al. Clinical severity of Alzheimer’s disease is associated with PIB uptake in PET. Neurobiol Aging. 2009;30:1902–9.

    Article  CAS  PubMed  Google Scholar 

  81. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer’s disease. Ann Neurol. 2008;63:621–31.

    Article  CAS  PubMed  Google Scholar 

  82. de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer’s disease. Ann N Y Acad Sci. 2007;1097:114–45.

    Article  PubMed  Google Scholar 

  83. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46:1625–32.

    CAS  PubMed  Google Scholar 

  84. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res. 2006;3:161–70.

    Article  CAS  PubMed  Google Scholar 

  85. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332–40.

    CAS  PubMed  Google Scholar 

  86. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA. 2000;97:6037–42.

    Article  CAS  PubMed  Google Scholar 

  87. Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease. Eur J Nucl Med Mol Imag. 2006;33:801–9.

    Article  Google Scholar 

  88. Walhovd KB, Fjell AM, Amlien I, Grambaite R, Stenset V, Bjornerud A, et al. Multimodal imaging in mild cognitive impairment: metabolism, morphometry and diffusion of the temporal-parietal memory network. Neuroimage. 2009;45:215–23.

    Article  CAS  PubMed  Google Scholar 

  89. Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131:665–80.

    Article  PubMed  Google Scholar 

  90. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imag. 2008;35:2169–81.

    Article  Google Scholar 

  91. Catana C, Wu Y, Judenhofer MS, Qi J, Pichler BJ, Cherry SR. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med. 2006;47:1968–76.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work has been supported in part by DFG grants (Deutsche Forschungsgemeinschaft) Project Numbers: DR 445/3-1, DR 445/4-1 (Drzezga). The author thanks Nicola Karina for the careful review of the manuscript.

Author information

Authors and Affiliations

  1. Harvard Medical School, Massachusetts General Hospital/Athinoula A. Martinos Center for Biomedical Imaging, Building 149, 13th Street, Room 2301, Charlestown, MA, 02129, USA

    Alexander Drzezga

  2. Nuklearmedizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

    Alexander Drzezga

Authors
  1. Alexander Drzezga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Drzezga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drzezga, A. Amyloid-plaque imaging in early and differential diagnosis of dementia. Ann Nucl Med 24, 55–66 (2010). https://doi.org/10.1007/s12149-009-0330-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-009-0330-9

Keywords

Search

Navigation